PreludeDx Unveils Groundbreaking Validation for AidaBreast™ Multi-Omic Test in Breast Cancer Recurrence Prediction

PreludeDx Announces Validation of AidaBreast™

PreludeDx, known for its pioneering work in breast cancer diagnostics, has unveiled the results of the first independent validation of AidaBreast™, a unique multi-omic test designed to estimate the risk of locoregional recurrence (LRR) in early-stage invasive breast cancer patients. This groundbreaking test not only predicts recurrence but also assesses the potential benefits of radiation therapy (RT) after breast-conserving surgery.

The validation study, which took place at the Royal Melbourne Hospital in Australia, involved over 400 women diagnosed with hormone receptor-positive (HR+) and HER2-negative invasive breast cancer. Participants received breast-conserving surgery followed by endocrine therapy and, depending on individual cases, radiation therapy. The results of this study reinforce the findings from PreludeDx’s earlier validation tests and mark a significant advance in personalized cancer treatment.

AidaBreast categorizes patients into 'Low Risk' and 'Elevated Risk' groups based on their tumor biology. The Elevated Risk group can benefit from targeted insights identifying which women may experience significant advantages from radiation therapy, as opposed to those for whom the therapy could be unnecessary.

Dr. Bruce Mann, the Principal Investigator of the study, emphasized the power of this independent validation, stating that "AidaBreast is prognostic for LRR risk and predictive for RT benefit, providing clinical insights beyond what clinicopathological evaluations can offer. This tool is a game changer for the treatment landscape of early-stage invasive breast cancer."

A New Level of Confidence and Decision-Making

AidaBreast utilizes advanced multi-omic technology that assesses both RNA and protein expressions along with spatial biology, ensuring a comprehensive understanding of an individual's tumor biology. Dan Forche, CEO of PreludeDx, mentioned, "For the first time, patients and their healthcare providers have a scientifically-backed tool for Stage I and IIa breast cancer, empowering them to collaboratively make informed choices regarding radiation therapy."

This innovative test represents a critical step forward, as the development of tools like AidaBreast answers fundamental questions regarding the necessity and benefit of radiation therapy in early-stage breast cancer patients, creating an integrated and data-driven approach to treatment.

Moreover, AidaBreast sets itself apart as the only test available that offers both prognostic and predictive insights for radiation intervention within this patient demographic. Dr. Troy Bremer, Chief Scientific Officer, pointed out, "Previous evaluations in breast cancer primarily focused on metastatic risks and chemotherapy advantages, whereas our test uniquely considers both recurrence likelihood and potential RT benefits—combining methodologies to produce a robust clinical assessment."

Continuation of PreludeDx's Commitment

AidaBreast follows in the footsteps of PreludeDx’s earlier success with DCISionRT®, a well-regarded test that has significantly influenced decision-making related to radiation therapy in patients with ductal carcinoma in situ (DCIS). With a shared mission to bring precise diagnostic solutions to breast cancer treatment, PreludeDx aims to deliver innovative tools that enhance patient outcomes while also striving to lower healthcare expenses.

"AidaBreast brings forth a new level of clarity for women faced with decisions concerning early-stage invasive breast cancer," Forche summarized. "We aim to ensure that women have the utmost clarity concerning their treatment choices so they can embark on informed journeys towards recovery and improved quality of life."

In conclusion, as the healthcare landscape evolves, PreludeDx is setting a precedent with actionable insights derived from integrative tests like AidaBreast. Health practitioners and patients alike are encouraged to remain engaged in the continuous journey of understanding and managing breast cancer risk in an informed and empowered manner.

About PreludeDx

Founded in 2009 and rooted in technology from the University of California San Francisco, PreludeDx specializes in personalized breast cancer diagnostic tools. The company is devoted to developing innovative solutions that facilitate impactful changes in treatment choices. For additional information on PreludeDx and its commitment to improving patient outcomes, visit PreludeDx. Follow on social media platforms including X, LinkedIn, Instagram, and Facebook to stay updated on initiatives aimed at enhancing women's health.